Vignesh T. Packiam, MD, director of Clinical and Translational Research in Urologic Oncology and a urologic oncologist in the Urologic Oncology Program at Rutge
Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer. Intravesical sequential gemcitabine-docetaxel may be a feasible alternative to BCG for high-risk nonmuscle-invasive bladder cancer (NMIBC).
Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer. Intravesical sequential gemcitabine-docetaxel may be a feasible alternative to BCG for high-risk nonmuscle-invasive bladder cancer (NMIBC).
The combination of gemcitabine and docetaxel conferred superior high-grade recurrence-free survival compared with standard therapy among adults with high-risk nonmuscle-invasive bladder cancer, results of a retrospective study showed.Patients who received the chemotherapy combination also had a lower frequency of treatment discontinuation than those who received bacillus Calmette-Guérin (BCG),